亚甲蓝不能改善左心室辅助装置植入后血管麻痹
本研究探讨亚甲蓝(MB)对左心室辅助装置(LVAD)植入后血管麻痹的疗效。
要点
- MB可短暂降低去甲肾上腺素和血管加压素需求,但未改善临床结局。
- MB组与对照组在院内死亡率、并发症及终末器官功能障碍方面无差异。
- 术中或术后给药对血流动力学和结局无显著影响。
核心结论
- 亚甲蓝虽可能影响血管加压药需求,但未改善LVAD植入后血管麻痹患者的临床结局,且给药时机不影响结果。
主要发现
- MB组去甲肾上腺素需求从141 ng/kg per min(95%CI 81-201)短暂降至117 ng/kg per min(95%CI 58-176;P=.022)。
- MB组血管加压素需求从4.8 U/h(95%CI 3.8-5.8)延迟降至4.0 U/h(95%CI 2.8-5.1;P=.004)。
- MB组与对照组在院内死亡率、术后并发症及终末器官功能障碍方面无差异。
- 术中给药(n=15)与术后给药(n=12)患者在平均动脉压、血管加压药需求或结局方面无差异。
- 整个研究队列加权总死亡率为8.8%。
关键数值与推荐
- MB总剂量中位数为1.9 mg/kg(四分位距1.2-2.2 mg/kg)。
临床怎么用
- 不推荐常规使用亚甲蓝来改善LVAD植入后血管麻痹的临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vasoplegia is a frequent complication of left ventricular assist device (LVAD) implantation. We investigated the effectiveness of methylene blue (MB) for vasoplegia in LVAD recipients. METHODS: Twenty-seven patients received MB for vasoplegia after LVAD implantation and met study criteria between March 2015 and May 2018. Propensity score inverse probability weighting identified 41 controls who did not receive MB for post-LVAD vasoplegia. Clinical outcomes were compared between control and MB groups and between patients who received doses during (n = 15) and after surgery (n = 12). Hemodynamics and vasopressor requirements were analyzed using analysis of covariance. RESULTS: Median total MB dose was 1.9 mg/kg (interquartile range, 1.2-2.2 mg/kg). Methylene blue recipients experienced a transient initial decline in norepinephrine requirement from 141 ng/kg per min (95% confidence interval [CI], 81-201 ng/kg per min) to 117 ng/kg per min (95% CI, 58-176 ng/kg per min; P = .022) and a delayed decline in vasopressin from 4.8 U/h (95% CI, 3.8-5.8 U/h) to 4.0 U/h (95% CI, 2.8-5.1 U/h) (P = .004). In-hospital mortality, postoperative complications, and end-organ dysfunction did not differ from those of controls. There were no observed differences in mean arterial pressure, vasopressor requirements, or outcomes between patients who received doses during or after surgery. Weighted overall mortality in the entire study cohort was 8.8%. CONCLUSIONS: Although MB may affect vasopressor requirements, clinical outcomes in vasoplegia after LVAD implantation did not improve and were not affected by the timing of administration.
引用
- Saha A, Jennings DL, Ning Y, et al. Methylene Blue Does Not Improve Vasoplegia After Left Ventricular Assist Device Implantation. Ann Thorac Surg. 2020. PMID: 32758558. doi:10.1016/j.athoracsur.2020.05.172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。